Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M.
Kucine N, et al. Among authors: mullighan cg.
Blood. 2015 Nov 26;126(22):2479-83. doi: 10.1182/blood-2015-03-635821. Epub 2015 Oct 6.
Blood. 2015.
PMID: 26443624
Free PMC article.
Clinical Trial.